Apatinib as maintenance therapy following standard first‐line chemotherapy in extensive disease small cell lung cancer: A phase II single‐arm trial

BACKGROUND: There is a need for the development of therapies to delay cancer progression and prolong survival after initial chemotherapy for the treatment of small cell lung cancer (SCLC). Since apatinib has been found to exert promising effects on cancer patients after standard first‐line chemother...

Descripción completa

Detalles Bibliográficos
Autores principales: Teng, Fei, Xing, Puyuan, Yang, Ke, Gao, Lizhen, Tian, Zhongqiu, Li, Junling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841707/
https://www.ncbi.nlm.nih.gov/pubmed/35029038
http://dx.doi.org/10.1111/1759-7714.14298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841707/
https://www.ncbi.nlm.nih.gov/pubmed/35029038
http://dx.doi.org/10.1111/1759-7714.14298

Ejemplares similares